Matching articles for "Mifeprex"
In Brief: Alternatives to Mifepristone for Medication Abortion
The Medical Letter on Drugs and Therapeutics • June 26, 2023; (Issue 1679)
The possibility that use of mifepristone (Mifeprex,
and generics) may be restricted has led to questions
about alternatives for medication...
The possibility that use of mifepristone (Mifeprex,
and generics) may be restricted has led to questions
about alternatives for medication abortion.
In Brief: Expanded Access to Mifepristone
The Medical Letter on Drugs and Therapeutics • February 20, 2023; (Issue 1670)
First approved in 2000 for termination of pregnancies
of ≤49 days' gestation, the indication for the oral
antiprogestin mifepristone (Mifeprex, and generics)
was expanded in 2016 to include pregnancies...
First approved in 2000 for termination of pregnancies
of ≤49 days' gestation, the indication for the oral
antiprogestin mifepristone (Mifeprex, and generics)
was expanded in 2016 to include pregnancies of
up to 10 weeks' gestation. A single 200-mg oral
dose of mifepristone followed 24-48 hours later by
a single 800-mcg buccal dose of the prostaglandin
analog misoprostol terminates early intrauterine
pregnancies in about 95% of women.
In Brief: Mifepristone by Mail for Pregnancy Termination
The Medical Letter on Drugs and Therapeutics • January 24, 2022; (Issue 1642)
The FDA has removed the requirement that
mifepristone (Mifeprex, and generics), a progestin
receptor antagonist approved for use in a regimen with
the prostaglandin E1 analog misoprostol (Cytotec,
and...
The FDA has removed the requirement that
mifepristone (Mifeprex, and generics), a progestin
receptor antagonist approved for use in a regimen with
the prostaglandin E1 analog misoprostol (Cytotec,
and generics) for medical termination of pregnancy,
must be dispensed in person to the patient.
Mifepristone (Mifeprex) Label Changes
The Medical Letter on Drugs and Therapeutics • April 25, 2016; (Issue 1493)
The FDA has approved several significant changes in
the labeling of mifepristone (Mifeprex – Danco), an oral
antiprogestin that has been used in the US for more than
15 years for termination of...
The FDA has approved several significant changes in
the labeling of mifepristone (Mifeprex – Danco), an oral
antiprogestin that has been used in the US for more than
15 years for termination of intrauterine pregnancy. It
has generally been used with the prostaglandin analog
misoprostol (Cytotec, and generics).
Misoprostol for Miscarriage
The Medical Letter on Drugs and Therapeutics • March 4, 2013; (Issue 1411)
Misoprostol (Cytotec, and generics), a prostaglandin E1
analog FDA-approved for prevention of NSAID-induced
gastric ulcers and, when taken with mifepristone
(Mifeprex), for termination of early intrauterine...
Misoprostol (Cytotec, and generics), a prostaglandin E1
analog FDA-approved for prevention of NSAID-induced
gastric ulcers and, when taken with mifepristone
(Mifeprex), for termination of early intrauterine pregnancy,
has also been used off-label for years for medical
management of first-trimester spontaneous abortion
(miscarriage).
Mifepristone (RU 486)
The Medical Letter on Drugs and Therapeutics • October 30, 2000; (Issue 1091)
Mifepristone (RU 486; Mifeprex - Danco), an antiprogestin, has been approved by the FDA for termination of intrauterine pregnancies of 49 days or less. It is generally used with misoprostol (Cytotec - Searle),...
Mifepristone (RU 486; Mifeprex - Danco), an antiprogestin, has been approved by the FDA for termination of intrauterine pregnancies of 49 days or less. It is generally used with misoprostol (Cytotec - Searle), an E1 prostaglandin analog marketed in the USA only for prevention of gastric ulcers.